ConductScience.org, home

Paper39375712

FANCA promotes lung adenocarcinoma progression and is a potential target for epitope vaccine immunotherapy.

Kang Y and 6 others. J Transl Med, 2024. Cited by 3 papers, by iCite.

Cite this record

ConductScience Library. FANCA promotes lung adenocarcinoma progression and is a potential target for epitope vaccine immunotherapy. Papers, record 39375712. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39375712

Download JSON
Cell line
PC-9154 papers
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
FANCA promotes lung adenocarcinoma progression and is a potential target for epitope vaccine immunotherapy.
PubMed
Journal
J Transl Med
PubMed
Year
2024
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
3
iCite
Relative citation ratio, by iCite
0.27, provisional
iCite
Revised in PubMed
2026-07-18
PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Kang YYanli
2Zhong RRuifang
3Gan YYuhan
4You JJianbin
5Chen JJinhua
6Chen FFalin
7Chen LLiangyuanhttps://orcid.org/0000-0002-5334-1656

Source PubMed

Download CSV of authors

Topics20

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Lung NeoplasmsMajor topic
ImmunotherapyMajor topic
EpitopesMajor topic
Disease ProgressionMajor topic
Cancer VaccinesMajor topic
Adenocarcinoma of LungMajor topic
Fanconi Anemia Complementation Group A ProteinMajor topic
Humans
Cell Line, Tumor
Cell Proliferation
Cell Movement
Male
Gene Expression Regulation, Neoplastic
Dendritic Cells
Female
Neoplasm Invasiveness
Prognosis
T-Lymphocytes, Cytotoxic
Middle Aged
Kaplan-Meier Estimate

Source PubMed

Download CSV of topics

Grants3

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
2023Y9279Joint Funds for the innovation of science and Technology, Fujian provincePubMed
2020QH1177Startup Fund for scientific research, Fujian Medical UniversityPubMed
2022QNA004Fujian Provincial Health Technology ProjectPubMed

Source PubMed

Download CSV of grants

References34

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
138390340Single-cell and Bulk RNA-Seq reveal angiogenic heterogeneity and microenvironmental features to evaluate prognosis and therapeutic response in lung adenocarcinoma.Front Immunol2024https://conductscience.org/library/papers/38390340PubMed
229098742A comprehensive approach to identification of pathogenic FANCA variants in Fanconi anemia patients and their families.Hum Mutat2018https://conductscience.org/library/papers/29098742PubMed
336682439Artificial intelligence in lung cancer diagnosis and prognosis: Current application and future perspective.Semin Cancer Biol2023https://conductscience.org/library/papers/36682439PubMed
435596788Fanconi anemia: current insights regarding epidemiology, cancer, and DNA repair.Hum Genet2022https://conductscience.org/library/papers/35596788PubMed
533811125Therapeutic Targeting of the Tumor Microenvironment.Cancer Discov2021https://conductscience.org/library/papers/33811125PubMed
631251079Elevated FANCA expression determines a worse prognosis in chronic lymphocytic leukemia and interferes with p53 function.FASEB J2019https://conductscience.org/library/papers/31251079PubMed
732929195Cytotoxic CD8+ T cells in cancer and cancer immunotherapy.Br J Cancer2021https://conductscience.org/library/papers/32929195PubMed
821982300Open Babel: An open chemical toolbox.J Cheminform2011https://conductscience.org/library/papers/21982300PubMed
935280757Clinical Benefit With PARP Inhibitor for Pathogenic Germline FANCA-Mutated Relapsed Epithelial Ovarian Cancer: A Case Report.Front Oncol2022https://conductscience.org/library/papers/35280757PubMed
1035371328Next-generation Sequencing Reveals Age-dependent Genetic Underpinnings in Lung adenocarcinoma.J Cancer2022https://conductscience.org/library/papers/35371328PubMed
1122009319NetMHCcons: a consensus method for the major histocompatibility complex class I predictions.Immunogenetics2012https://conductscience.org/library/papers/22009319PubMed
1234278794AutoDock Vina 1.2.0: New Docking Methods, Expanded Force Field, and Python Bindings.J Chem Inf Model2021https://conductscience.org/library/papers/34278794PubMed
1329511158Cytokine-induced killer cells as a feasible adoptive immunotherapy for the treatment of lung cancer.Cell Death Dis2018https://conductscience.org/library/papers/29511158PubMed
1428783718Integrative clinical genomics of metastatic cancer.Nature2017https://conductscience.org/library/papers/28783718PubMed
1535747792Serum and Serum Exosomal CircRNAs hsa_circ_0001492, hsa_circ_0001439, and hsa_circ_0000896 as Diagnostic Biomarkers for Lung Adenocarcinoma.Front Oncol2022https://conductscience.org/library/papers/35747792PubMed
1633918752Generating New FANCA-Deficient HNSCC Cell Lines by Genomic Editing Recapitulates the Cellular Phenotypes of Fanconi Anemia.Genes (Basel)2021https://conductscience.org/library/papers/33918752PubMed
1731932876Identification of two HLA-A*0201 immunogenic epitopes of lactate dehydrogenase C (LDHC): potential novel targets for cancer immunotherapy.Cancer Immunol Immunother2020https://conductscience.org/library/papers/31932876PubMed
1837573408FANCA deficiency promotes leukaemic progression by allowing the emergence of cells carrying oncogenic driver mutations.Oncogene2023https://conductscience.org/library/papers/37573408PubMed
1936898365Evaluating Germline Testing Panels in Southern African Males With Advanced Prostate Cancer.J Natl Compr Canc Netw2023https://conductscience.org/library/papers/36898365PubMed
2015633217Prediction of HLA-A2-restricted CTL epitope specific to HCC by SYFPEITHI combined with polynomial method.World J Gastroenterol2005https://conductscience.org/library/papers/15633217PubMed

See all 34 referencesDownload CSV of references

Cited by3

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.

PMIDTitleJournalYearIn PapersSource
41345681Effect of antiserum against recombinant EGr_09888 on the in vitro development of Echinococcus granulosus protoscoleces.Parasitol Res2025https://conductscience.org/library/papers/41345681PubMed
40270965Identification of new HLA-A*0201-restricted cytotoxic T lymphocyte epitopes from LDHC in lung adenocarcinoma.Front Immunol2025https://conductscience.org/library/papers/40270965PubMed
39850875Combining single-cell analysis and molecular docking techniques to construct a prognostic model for colon adenocarcinoma and uncovering inhibin subunit βb as a novel therapeutic target.Front Immunol2024https://conductscience.org/library/papers/39850875PubMed

Download CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
FANCA2175PubTator's text mininghttps://conductscience.org/library/genes/2175

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39375712

GET https://conductscience.org/api/papers/v1/39375712/references?page=2